Compare Stocks: ICCC, BIOA, ENTA, and EYPT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$7.18 +1.8%	$11.52	$5.04 ▼ $25.95	$323.57M	0.94	671,500 shs	800,137 shs
ENTA Enanta Pharmaceuticals	$12.61 +6.1%	$13.14	$7.05 ▼ $17.15	$346.01M	0.93	236,589 shs	349,326 shs
EYPT Eyepoint Pharmaceuticals	$3.31 -8.6%	$7.61	$3.27 ▼ $19.11	$312.09M	1.63	3.44 million shs	3.29 million shs
ICCC ImmuCell	$9.88 -0.5%	$10.32	$4.52 ▼ $12.10	$90.14M	0.54	13,895 shs	4,451 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	0.00%	-12.53%	-26.94%	-71.74%	+30.07%
ENTA Enanta Pharmaceuticals	0.00%	-2.62%	-12.65%	-18.13%	+50.38%
EYPT Eyepoint Pharmaceuticals	0.00%	-5.97%	-19.20%	-74.34%	-73.96%
ICCC ImmuCell	0.00%	-0.20%	-0.10%	+0.20%	+64.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$7.18 +1.8%	$11.52	$5.04 ▼ $25.95	$323.57M	0.94	671,500 shs	800,137 shs
ENTA Enanta Pharmaceuticals	$12.61 +6.1%	$13.14	$7.05 ▼ $17.15	$346.01M	0.93	236,589 shs	349,326 shs
EYPT Eyepoint Pharmaceuticals	$3.31 -8.6%	$7.61	$3.27 ▼ $19.11	$312.09M	1.63	3.44 million shs	3.29 million shs
ICCC ImmuCell	$9.88 -0.5%	$10.32	$4.52 ▼ $12.10	$90.14M	0.54	13,895 shs	4,451 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	0.00%	-12.53%	-26.94%	-71.74%	+30.07%
ENTA Enanta Pharmaceuticals	0.00%	-2.62%	-12.65%	-18.13%	+50.38%
EYPT Eyepoint Pharmaceuticals	0.00%	-5.97%	-19.20%	-74.34%	-73.96%
ICCC ImmuCell	0.00%	-0.20%	-0.10%	+0.20%	+64.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIOA BioAge Labs	2.71	Moderate Buy	$36.57	409.35% Upside
ENTA Enanta Pharmaceuticals	2.67	Moderate Buy	$21.00	66.53% Upside
EYPT Eyepoint Pharmaceuticals	2.27	Hold	$25.70	676.44% Upside
ICCC ImmuCell	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ICCC, BIOA, ENTA, and EYPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	ENTA Enanta Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/9/2026	BIOA BioAge Labs	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/8/2026	BIOA BioAge Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/2/2026	EYPT Eyepoint Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$20.00 ➝ $4.00
9/1/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/18/2026	EYPT Eyepoint Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Sector Perform	$5.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
8/17/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIOA BioAge Labs	$8.99M	36.66	N/A	N/A	$7.59 per share	0.95
ENTA Enanta Pharmaceuticals	$65.32M	5.62	N/A	N/A	$3.03 per share	4.16
EYPT Eyepoint Pharmaceuticals	$31.37M	9.10	N/A	N/A	$3.70 per share	0.89
ICCC ImmuCell	$27.64M	3.25	$0.19 per share	51.48	$2.99 per share	3.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIOA BioAge Labs	-$80.61M	-$2.38	N/A	N/A	N/A	-912.26%	-28.99%	-27.09%	N/A
ENTA Enanta Pharmaceuticals	-$81.89M	-$2.41	N/A	N/A	N/A	-96.89%	-61.84%	-20.70%	11/16/2026 (Estimated)
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
ICCC ImmuCell	-$1.04M	$0.08	123.52	N/A	N/A	2.57%	2.69%	1.76%	11/12/2026 (Estimated)

Latest ICCC, BIOA, ENTA, and EYPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	$0.20	+$0.15	$0.20	$5.40 million	$7.19 million
8/10/2026	Q3 2026	ENTA Enanta Pharmaceuticals	-$0.5095	-$0.67	-$0.1605	-$0.67	$16.76 million	$14.36 million
8/5/2026	Q2 2026	BIOA BioAge Labs	-$0.65	-$0.58	+$0.07	-$0.58	N/A	$2.45 million
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIOA BioAge Labs	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIOA BioAge Labs	N/A	17.19	17.19
ENTA Enanta Pharmaceuticals	N/A	3.76	3.76
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
ICCC ImmuCell	0.22	4.75	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIOA BioAge Labs	N/A
ENTA Enanta Pharmaceuticals	94.99%
EYPT Eyepoint Pharmaceuticals	99.41%
ICCC ImmuCell	13.47%

Insider Ownership

Company	Insider Ownership
BIOA BioAge Labs	17.55%
ENTA Enanta Pharmaceuticals	11.48%
EYPT Eyepoint Pharmaceuticals	5.13%
ICCC ImmuCell	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIOA BioAge Labs	62	45.90 million	37.84 million	N/A
ENTA Enanta Pharmaceuticals	120	29.12 million	25.78 million	Optionable
EYPT Eyepoint Pharmaceuticals	214	86.21 million	81.79 million	Optionable
ICCC ImmuCell	73	9.08 million	8.56 million	Not Optionable

ICCC, BIOA, ENTA, and EYPT Headlines

Recent News About These Companies

Spero Therapeutics (NASDAQ:SPRO) vs. ImmuCell (NASDAQ:ICCC) Head-To-Head Comparison

September 18, 2026 | americanbankingnews.com

ImmuCell (NASDAQ:ICCC) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

September 9, 2026 | marketbeat.com

ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average - What's Next?

September 1, 2026 | marketbeat.com

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2

August 27, 2026 | zacks.com

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

August 13, 2026 | finance.yahoo.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

August 13, 2026 | globenewswire.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

August 6, 2026 | globenewswire.com

ImmuCell: First Defense With Better Execution

July 24, 2026 | seekingalpha.com

ImmuCell posts strong preliminary Q2 sales on US demand

July 11, 2026 | msn.com

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand

July 10, 2026 | zacks.com

ImmuCell reports preliminary Q2 sales increase of 11.5% to $7.2M

July 9, 2026 | msn.com

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

July 9, 2026 | globenewswire.com

Insider Buying: ImmuCell (NASDAQ:ICCC) CEO Acquires $75,920.00 in Stock

June 23, 2026 | insidertrades.com

ICCC's Valuation Remains Premium: Is it Worth Overpaying for?

June 18, 2026 | zacks.com

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand

May 25, 2026 | zacks.com

ImmuCell (ICCC) Q1 2026 Earnings Transcript

May 17, 2026 | aol.comA

ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth

May 17, 2026 | finance.yahoo.com

ImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call Transcript

May 16, 2026 | insidermonkey.com

ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript

May 15, 2026 | seekingalpha.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026

May 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ICCC, BIOA, ENTA, and EYPT Company Descriptions

BioAge Labs NASDAQ:BIOA

$7.18 +0.13 (+1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$7.15 -0.03 (-0.42%)

As of 07:48 PM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Enanta Pharmaceuticals NASDAQ:ENTA

$12.61 +0.73 (+6.14%)

Closing price 04:00 PM Eastern

Extended Trading

$12.62 +0.01 (+0.04%)

As of 07:30 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$3.31 -0.31 (-8.56%)

Closing price 04:00 PM Eastern

Extended Trading

$3.35 +0.04 (+1.24%)

As of 07:50 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

ImmuCell NASDAQ:ICCC

$9.88 -0.05 (-0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$10.00 +0.12 (+1.21%)

As of 07:30 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ICCC, BIOA, ENTA, and EYPT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ICCC, BIOA, ENTA, and EYPT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ICCC, BIOA, ENTA, and EYPT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ICCC, BIOA, ENTA, and EYPT Company Descriptions

BioAge Labs NASDAQ:BIOA

Enanta Pharmaceuticals NASDAQ:ENTA

Eyepoint Pharmaceuticals NASDAQ:EYPT

ImmuCell NASDAQ:ICCC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ICCC, BIOA, ENTA, and EYPT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ICCC, BIOA, ENTA, and EYPT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ICCC, BIOA, ENTA, and EYPT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ICCC, BIOA, ENTA, and EYPT Company Descriptions

BioAge Labs NASDAQ:BIOA

Enanta Pharmaceuticals NASDAQ:ENTA

Eyepoint Pharmaceuticals NASDAQ:EYPT

ImmuCell NASDAQ:ICCC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools